Thiocarlide

Clinical data
ATC code	J04AD02 (WHO)
Identifiers
IUPAC name 1,3-bis[4-(3-methylbutoxy)phenyl]thiourea
CAS Number	910-86-1 N
PubChem CID	3001386
ChemSpider	2272774 Y
UNII	43M23X81Y2
KEGG	D07246
ChEMBL	ChEMBL214920 Y
CompTox Dashboard (EPA)	DTXSID70238358
ECHA InfoCard	100.011.824
Chemical and physical data
Formula	C23H32N2O2S
Molar mass	400.58 g·mol−1
3D model (JSmol)	Interactive image
SMILES S=C(Nc1ccc(OCCC(C)C)cc1)Nc2ccc(OCCC(C)C)cc2
InChI InChI=1S/C23H32N2O2S/c1-17(2)13-15-26-21-9-5-19(6-10-21)24-23(28)25-20-7-11-22(12-8-20)27-16-14-18(3)4/h5-12,17-18H,13-16H2,1-4H3,(H2,24,25,28) Y Key:BWBONKHPVHMQHE-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Thiocarlide (or tiocarlide or isoxyl) is a thiourea drug used in the treatment of tuberculosis, inhibiting synthesis of oleic acid and tuberculostearic acid.^[1]

Thiocarlide has considerable antimycobacterial activity in vitro and is effective against multi-drug resistant strains of Mycobacterium tuberculosis.^[2] Isoxyl inhibits M. bovis with six hours of exposure, which is similar to isoniazid and ethionamide, two other prominent anti-TB drugs. Unlike these two drugs, however, isoxyl also partially inhibits the synthesis of fatty acids.^{[citation needed]}

Thiocarlide was developed by a Belgian company, Continental Pharma S.A. Belgo-Canadienne in Brussels, Belgium. The head researcher was Professor N. P. Buu-Hoi, head of Continental Pharma's Research Division.^{[citation needed]}